Albulena Mecinaj
@AlbulenaMecinaj
Followers
79
Following
61
Media
1
Statuses
11
Cardiology Fellow in Oslo/Akershus, Ph.D candidate | Cardio-Oncology |PRADA trials
Oslo, Norge
Joined October 2019
📖 💖 It’s time for the next chapter in cardio-oncology… Join us for the inaugural #ESCardioOnco2025 conference, where specialists in cardiology, oncology, haematology and related fields will come together to share knowledge and build valuable connections in this dynamic and
2
30
61
For #WorldCancerDay #WorldCancerDay2022 Venous #thrombosis #VTE is complication in #cancer ▶️📈mortality. No data low-dose anticoagulation as 2nd prophylaxis for VTE in pts. Larsen et al @CEHRAhus show few VTE and #bleeding post 12-36 months +low-dose FXa-inhibitor apixaban.
0
4
7
Can sacubitril/valsartan prevent cardiotoxicity? PRADA II will assess if sacubitril/valsartan given concomitantly with early breast cancer treatment regimens including anthracyclines, with or without trastuzumab, may prevent cardiac dysfunction. @siri_lh @Gulati_Norway @OmlandRn
1
8
38
We are proud to present the results of the extended follow-up of the PRADA trial! https://t.co/fFk2ahdLVF
@AlbulenaMecinaj @Gulati_Norway @OmlandRn
@Ahus_no #CircACC2021 #AHAJournals #ACC21 @AHAScience
ahajournals.org
Background: Adjuvant breast cancer therapy containing anthracyclines with or without anti–human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with cancer treatment–re...
PRADA: Candesartan improves LVEDV and GLS in long-term f/u after anthracycline use for breast cancer , but did not prevent EF decline https://t.co/BCVcm7G0BH
#CircACC2021 #AHAJournals #ACC21 @AHAScience
0
6
9
PRADA: Candesartan improves LVEDV and GLS in long-term f/u after anthracycline use for breast cancer , but did not prevent EF decline https://t.co/BCVcm7G0BH
#CircACC2021 #AHAJournals #ACC21 @AHAScience
2
49
139
Great overview about prevention, detection and management of heart failure in patients treated for breast cancer!
link.springer.com
Current Heart Failure Reports - Long-term survival has increased significantly in breast cancer patients, and cardiovascular side effects are surpassing cancer-related mortality. We summarize risk...
0
1
4
0
3
5
#CardioOncology New ICOS Work Group of Young Investigators from 14 different countries stay tuned for forthcoming research
0
5
33
Best part of #GCOS2019 #GCOS - meeting old and new friends! @CarolCardioOnc @md_arianemacedo @patricia_tfm @oncology_cardio @Dr_Mike_Fradley and Drs Geeta Gulati and Albulena Mecinaj #Friends #Colaboration
2
6
21